Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Updated Safety and Efficacy of Venetoclax with Decitabine or Azacitidine in Treatment-Naive, Elderly Patients with Acute Myeloid Leukemia

Courtney D. DiNardo, MDMSc, Daniel A. Pollyea, MD, Brian A Jonas, MD PhD, Marina Konopleva, MD PhD, Vinod Pullarkat, MD MRCP, Andrew Wei, MBBS, PhD FRACP, FRCPA, Hagop M. Kantarjian, MD, Arnaud Pigneux, MD PhD, Christian Recher, MD PhD, John F Seymour, MB BS PhDFRACP, Martin Dunbar, DRPH, MS, Tu Xu, PhD, Mack Mabry, MD, Jalaja Potluri, MD, Keith Pratz, MD, Anthony Letai, MD PhD

Blood (2017) 130 (Supplement 1): 2628.

https://doi.org/10.1182/blood.V130.Suppl_1.2628.2628

Published: 2017

Journal Articles

Bone Marrow Hypocellularity Does Not Impair the Tolerability or Efficacy of Azacitidine (AZA) in Patients with Higher-Risk Myelodysplastic Syndromes Treated in the AZA-001 Study

John F Seymour, MB, BS, PhD, FRACP, John M. Bennett, MD, Alan F List, MD, Ghulam J. Mufti, MD, Steven D. Gore, MD, Pierre Fenaux, MD, PhD, Valeria Santini, MD, Joel Hetzer, PhD, Stephen Songer, PharmD, Barry S. Skikne, MD, C.L. Beach, PharmD

Blood (2012) 120 (21): 3808.

https://doi.org/10.1182/blood.V120.21.3808.3808

Published: 2012

Journal Articles

Surveillance PET-CT Scanning Is Useful in the First 18 Months Following Completion of Therapy for Patients with Diffuse Large B-Cell Lymphoma with IPI≥3.

Chan Y Cheah, MBBS, FRACP, FRCPA, Michael S Hofman, MBBS FRACP, Michael J. Dickinson, MBBS, FRACP, FRCPA, Andrew Wirth, MBBS, FRANZCR, David A Westerman, MBBS, FRACP, FRCPA, FFSc, Simon J. Harrison, MBBS MRCP (uk) MRCPath (uk) PhD, Kate Burbury, MBBS, FRACP, FRCPA, DPhil, Max Wolf, MBBS, FRACP, FRCPA, Elchanan H. Januszewicz, MBBS FRACP FRCPA, Kirsten Herbert, MD, BSci(Med), FRACP, PhD, Miles Prince, MD, FRACP, FRCPA, Dennis A Carney, MBBS FRACP FRCPA, David Ritchie, MBBS, FRACP, FRCPA, PhD, Rodney Hicks, MB BS, MD, FRACP, John F Seymour, MB, BS, PhD, FRACP

Blood (2012) 120 (21): 2652.

https://doi.org/10.1182/blood.V120.21.2652.2652

Published: 2012

Journal Articles

An Ongoing Phase 1/2a Study of ABT-263; Pharmacokinetics (PK), Safety and Anti-Tumor Activity in Patients (pts) with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL).

Andrew W. Roberts, MBBS, PhD, John F Seymour, MB, BS, PhD, FRACP, Jennifer R Brown, MD, PhD, William G Wierda, Thomas J. Kipps, MD, PhD, Dennis Carney, MBBS, FRACP, FRCPA, Hao Xiong, Ph.D., Yue Cui, PhD, Todd Busman, Sari Enschede, Andrew Krivoshik, Rod Humerickhouse

Blood (2009) 114 (22): 883.

https://doi.org/10.1182/blood.V114.22.883.883

Published: 2009

Journal Articles

The Majority of Chronic Myeloid Leukaemia Patients Who Cease Imatinib after Achieving a Sustained Complete Molecular Response (CMR) Remain in CMR, and Any Relapses Occur Early.

Davi D M Ross, Andrew Grigg, Anthony Schwarer, Christopher Arthur, Kerryn Loftus, Anthony K Mills, Robin Filshie, Ruth Columbus, John Reynolds, John F Seymour, MB, BS, PhD, FRACP, Susan Branford, Timothy Hughes

Blood (2008) 112 (11): 1102.

https://doi.org/10.1182/blood.V112.11.1102.1102

Published: 2008

Journal Articles

Delivery and Toxicity of Fludarabine-Based Combination Chemotherapy Regimens in Older Patients.

Mark N. Polizzotto, MB, BS, Constantine S. Tam, MB, BS, Henry Januszewicz, MB, BS, Miles Prince, MB, BS, MD, Max Wolf, MB, BS, John F. Seymour, MB, BS

Blood (2005) 106 (11): 3329.

https://doi.org/10.1182/blood.V106.11.3329.3329

Published: 2005

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Updated Safety and Efficacy of Venetoclax with Decitabine or Azacitidine in Treatment-Naive, Elderly Patients with Acute Myeloid Leukemia

Bone Marrow Hypocellularity Does Not Impair the Tolerability or Efficacy of Azacitidine (AZA) in Patients with Higher-Risk Myelodysplastic Syndromes Treated in the AZA-001 Study

Surveillance PET-CT Scanning Is Useful in the First 18 Months Following Completion of Therapy for Patients with Diffuse Large B-Cell Lymphoma with IPI≥3.

An Ongoing Phase 1/2a Study of ABT-263; Pharmacokinetics (PK), Safety and Anti-Tumor Activity in Patients (pts) with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL).

The Majority of Chronic Myeloid Leukaemia Patients Who Cease Imatinib after Achieving a Sustained Complete Molecular Response (CMR) Remain in CMR, and Any Relapses Occur Early.

Delivery and Toxicity of Fludarabine-Based Combination Chemotherapy Regimens in Older Patients.

Email alerts

ASH Publications

American Society of Hematology

Update search

Updated Safety and Efficacy of Venetoclax with Decitabine or Azacitidine in Treatment-Naive, Elderly Patients with Acute Myeloid Leukemia

Bone Marrow Hypocellularity Does Not Impair the Tolerability or Efficacy of Azacitidine (AZA) in Patients with Higher-Risk Myelodysplastic Syndromes Treated in the AZA-001 Study

Surveillance PET-CT Scanning Is Useful in the First 18 Months Following Completion of Therapy for Patients with Diffuse Large B-Cell Lymphoma with IPI≥3.

An Ongoing Phase 1/2a Study of ABT-263; Pharmacokinetics (PK), Safety and Anti-Tumor Activity in Patients (pts) with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL).

The Majority of Chronic Myeloid Leukaemia Patients Who Cease Imatinib after Achieving a Sustained Complete Molecular Response (CMR) Remain in CMR, and Any Relapses Occur Early.

Delivery and Toxicity of Fludarabine-Based Combination Chemotherapy Regimens in Older Patients.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only